Advertisement

Clinical Pharmacokinetics

, Volume 46, Issue 3, pp 247–259 | Cite as

Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin

  • Ridia Chandra
  • Ping Liu
  • Jeanne D. Breen
  • Jeannine Fisher
  • Charles Xie
  • Robert LaBadie
  • Rebecca J. Benner
  • Lisa J. Benincosa
  • Amarnath SharmaEmail author
Original Research Article

Abstract

Background and objective

A novel oral, extended-release, microsphere formulation of azithromycin (AZSR) was developed to improve the gastrointestinal tolerability profile while allowing administration of an entire treatment course of azithromycin in a single dose. Several phase I clinical pharmacology studies were conducted to (i) identify a well-tolerated single-dose formulation that met a predefined exposure target; and (ii) evaluate the effect of food and antacid on the absorption of this formulation. Of these, five pivotal studies are described here.

Methods

The pharmacokinetic profile of AZSR was compared with that of the commercially available immediate-release azithromycin formulation (AZM) in an open-label, crossover, single-dose study (Study A), and their gastrointestinal tolerability profiles were compared in an observer-blind, parallel group, single-dose study (Study B). The effects of food (a high-fat meal and a standard meal) and antacid (a single 20mL dose of Maalox® Regular Strength, containing magnesium hydroxide, aluminium hydroxide and simethicone) on the absorption of azithromycin from AZSR were evaluated in three separate open-label, crossover, single-dose studies (Studies C, D and E). Healthy adult subjects were enrolled in all five studies, and all subjects were evaluable for tolerability. The dose used for all azithromycin formulations was 2.0g. Serum azithromycin concentrations were determined using a validated high-performance liquid chromatography/electrochemical detection method, and pharmacokinetic parameters were analysed using noncompartmental methods.

Results

377 subjects received a single 2.0g dose of azithromycin as AZSR and/or AZM in the five studies. Compared with AZM, AZSR had a slower absorption rate (57% decrease in the mean peak concentration [Cmax] and an approximate 2.5-hour delay in the time to reach Cmax [tmax]), with a mean relative bioavailability of 82.8%, which met the predefined exposure target (at least 80% bioavailability relative to AZM). Compared with AZM, AZSR was associated with significantly lower rates of nausea and vomiting. A high-fat meal increased the mean area under the serum concentration-time curve [AUC] from time zero to 72 hours post-dose (AUC72h) by 23% and increased the Cmax of azithromycin by 115%. A standard meal increased the mean Cmax by 119% but had no clinically significant effect on the AUC72h. AZSR appeared to be better tolerated in the fasted state than in the fed state. The AUC72h and Cmax of AZSR were not significantly affected by co-administration with a single dose of antacid.

Conclusions

The extended-release microsphere formulation of azithromycin, AZSR, allows administration of an entire therapeutic course of azithromycin as a well-tolerated single 2.0g dose. This formulation should be administered on an empty stomach and can be co-administered with antacids.

Keywords

Azithromycin Acceptance Interval Telithromycin Standard Meal Magnesium Hydroxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We thank Dr T. Hunt and the staff of PPD Development, LLC, Dr A.K. Copa and the staff of PRACS Institute, Dr J. Carlson (Fargo, ND, USA), Dr M. Gutierrez (Fort Lauderdale, FL, USA), Dr A. Laurent (Austin, TX, USA) and Dr N. Abdou (Lenexa, KA, USA) and their staff for the clinical conduct of these studies. We thank our assay specialist, Penelope Crownover, and BAS Analytics (West Lafayette, IN, USA) for the analytical assay support. All of the authors are employees of Pfizer, Inc. and are eligible to receive Pfizer stock and stock options. All studies were sponsored by Pfizer, Inc.

References

  1. 1.
    Pfizer, Inc. Zithromax® (azithromycin tablets) and (azithromycin for oral suspension) [online]. New York (NY): Pfizer, Inc., 2004. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zithromax.pdf [Accessed 2007 Jan 30]
  2. 2.
    Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (3Suppl.): 38–44Google Scholar
  3. 3.
    Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31 (ESuppl.): 39–50CrossRefGoogle Scholar
  4. 4.
    Girard D, Bergeron JM, Milisen WB, et al. Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. J Antimicrob Chemother 1993; 31 (ESuppl.): 17–28CrossRefGoogle Scholar
  5. 5.
    Girard D, Finegan SM, Dunne MW, et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56: 365–71PubMedCrossRefGoogle Scholar
  6. 6.
    Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection: re-evaluating current antibiotic therapy. Respir Med 2001; 95(A Suppl.): S12–9PubMedCrossRefGoogle Scholar
  7. 7.
    Pfizer, Inc. Zithromax® (azithromycin for injection): for IV infusion only [online]. New York (NY): Pfizer, Inc., 2003. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zithromaxIV.pdf [Accessed 2007 Jan 30]
  8. 8.
    Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drag Saf 1993; 9: 346–64CrossRefGoogle Scholar
  9. 9.
    Weber Jr FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485–90PubMedGoogle Scholar
  10. 10.
    Data on file, Pfizer Inc., 2002Google Scholar
  11. 11.
    US FDA. Draft guidance for industry: bioavailability and bio-equivalence studies for orally administered drag products — general considerations [online]. Rockville (MD): US FDA, 2002. Available from URL: http://www.fda.gov/cder/guidance/4964dft.htm [Accessed 2007 Jan 30]
  12. 12.
    Taninaka C, Ohtani H, Hanada E, et al. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr B Biomed Sci Appl 2000; 738: 405–11PubMedCrossRefGoogle Scholar
  13. 13.
    Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001; 29 (2Suppl.): 11–5Google Scholar
  14. 14.
    Noreddin AM, Roberts D, Nichol K, et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46: 4029–34PubMedCrossRefGoogle Scholar
  15. 15.
    Zhanel GG, Johanson C, Hisanaga T, et al. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 2004; 54: 1072–7PubMedCrossRefGoogle Scholar
  16. 16.
    Darkes MJ, Perry CM. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2003; 2: 175–201PubMedCrossRefGoogle Scholar
  17. 17.
    Perez-Gorricho B, Ripoll M. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents 2003; 21: 222–8PubMedCrossRefGoogle Scholar
  18. 18.
    Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005; 118(7A Suppl.): 21S–8SPubMedCrossRefGoogle Scholar
  19. 19.
    Azithromycin extended-release (Zmax) for sinusitis and pneumonia. Med Lett Drags Ther 2005; 47: 78-80Google Scholar
  20. 20.
    Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128: 2230–7PubMedCrossRefGoogle Scholar
  21. 21.
    Pfizer, Inc. Zmax™ (azithromycin extended release) for oral suspension [online]. New York (NY): Pfizer, Inc., 2005. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zmax.pdf [Accessed 2007 Jan 30]
  22. 22.
    Feighner SD, Tan CP, McKee KK, et al. Receptor for motilin identified in the human gastrointestinal system. Science 1999; 284: 2184–8PubMedCrossRefGoogle Scholar
  23. 23.
    Takeshita E, Matsuura B, Dong M, et al. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol 2006; 41: 223–30PubMedCrossRefGoogle Scholar
  24. 24.
    Peeters TL, Bormans V, Vantrappen G. Comparison of motilin binding to crude homogenates of human and canine gastrointestinal smooth muscle tissue. Regul Pept 1988; 23: 171–82PubMedCrossRefGoogle Scholar
  25. 25.
    Data on file, Pfizer Inc., 1994Google Scholar
  26. 26.
    Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25 (ASuppl.): 39–47CrossRefGoogle Scholar
  27. 27.
    Hurlimann S, Michel K, Inauen W, et al. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers. Am J Gastroenterol 1996; 91: 1173–80PubMedGoogle Scholar
  28. 28.
    Data on file, Pfizer Inc., 2004Google Scholar
  29. 29.
    Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999; 43: 163–5PubMedGoogle Scholar
  30. 30.
    Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007 Jan; 51(1): 103–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Ridia Chandra
    • 1
  • Ping Liu
    • 1
  • Jeanne D. Breen
    • 1
  • Jeannine Fisher
    • 1
  • Charles Xie
    • 1
  • Robert LaBadie
    • 1
  • Rebecca J. Benner
    • 1
  • Lisa J. Benincosa
    • 1
  • Amarnath Sharma
    • 1
    Email author
  1. 1.Clinical R&DPfizer Global Research and DevelopmentNew LondonUSA

Personalised recommendations